Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent

Jiang, ZR; Wang, L; Liu, XS; Chen, C; Wang, BL; Wang, WL; Hu, C; Yu, KL; Qi, ZP; Liu, QW; Wang, AL; Liu, J; Hong, GC; Wang, WC; Liu, QS

Wang, WC; Liu, QS (corresponding author), Chinese Acad Sci, Hefei Inst Phys Sci, High Magnet Field Lab, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Peoples R China.; Liu, QS (corresponding author), Univ Sci & Technol China, Hefei 230026, Peoples R China.; Liu, QS (corresponding author), Chinese Acad Sci, Precis Targeted Therapy Discovery Ctr, Inst Technol Innovat, Hefei Inst Phys Sci, Hefei 230088, Peoples R China.; Wang, WC; Liu, QS (corresponding author), Precis Med Res Lab Anhui Prov, Hefei 230088, Peoples R China.; Hong, GC (corresponding author), Qingdao Shinan Dist Peoples Hosp, Qingdao 266002, Peoples R China.; Liu, QS (corresponding author), Anhui Univ, Inst Phys Sci & Informat Technol, Hefei 230601, Peoples R China.

ACTA PHARMACEUTICA SINICA B, 2020; 10 (3): 488

Abstract

Angiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway ......

Full Text Link